Adjuvant Sunitinib for High Risk Renal Cell Carcinoma: Not Ready for Prime Time
Dr. Alan H. Bryce, MD, argues that there is not yet enough substantive data and research to justify the FDA approving using adjuvant Sunitinib to treat high risk renal cell carcinoma.
Read More